Punctate inner choroidopathy immediately after COVID-19 infection: a case report
Abstract Background Punctate inner choroidopathy (PIC) is a rare idiopathic inflammatory multifocal chorioretinopathy. Although the etiology of PIC is unknown, it is proposed to be an autoimmune disease that arises in the context of polygenic susceptibility triggered by an environmental stimulus, su...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12886-022-02514-8 |
| _version_ | 1818518883706863616 |
|---|---|
| author | Manabu Miyata Sotaro Ooto Yuki Muraoka |
| author_facet | Manabu Miyata Sotaro Ooto Yuki Muraoka |
| author_sort | Manabu Miyata |
| collection | DOAJ |
| description | Abstract Background Punctate inner choroidopathy (PIC) is a rare idiopathic inflammatory multifocal chorioretinopathy. Although the etiology of PIC is unknown, it is proposed to be an autoimmune disease that arises in the context of polygenic susceptibility triggered by an environmental stimulus, such as infection. We reported a case of PIC immediately after COVID-19 infection. Case presentation A 25-year-old woman complained of blurred vision in the right eye six days after the symptoms of COVID-19 infection first appeared. The patient visited our hospital and underwent comprehensive ophthalmological examination 18 days after the initial COVID-19 symptoms. Based on the characteristic fundus features observed with multimodal imaging, retinal specialists made a diagnosis of PIC. The patient was affected with high myopia. As her general COVID-19 symptoms disappeared, the patient was prescribed oral prednisolone 30 mg/day for 14 days to treat PIC. Fundus abnormality decreased and her ocular symptoms improved. No side effects were observed, including the recurrence of general COVID-19 symptoms. Conclusion We experienced an extremely rare case of PIC immediately after COVID-19 infection and showed the potential safety and effectiveness of oral prednisolone in treating PIC in the active phase after the disappearance of the general COVID-19 infection symptoms. |
| first_indexed | 2024-12-11T01:16:22Z |
| format | Article |
| id | doaj.art-13b5c6a9eee742bdba2d77984cd51bfd |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-12-11T01:16:22Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-13b5c6a9eee742bdba2d77984cd51bfd2022-12-22T01:25:52ZengBMCBMC Ophthalmology1471-24152022-07-012211510.1186/s12886-022-02514-8Punctate inner choroidopathy immediately after COVID-19 infection: a case reportManabu Miyata0Sotaro Ooto1Yuki Muraoka2Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of MedicineDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of MedicineDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of MedicineAbstract Background Punctate inner choroidopathy (PIC) is a rare idiopathic inflammatory multifocal chorioretinopathy. Although the etiology of PIC is unknown, it is proposed to be an autoimmune disease that arises in the context of polygenic susceptibility triggered by an environmental stimulus, such as infection. We reported a case of PIC immediately after COVID-19 infection. Case presentation A 25-year-old woman complained of blurred vision in the right eye six days after the symptoms of COVID-19 infection first appeared. The patient visited our hospital and underwent comprehensive ophthalmological examination 18 days after the initial COVID-19 symptoms. Based on the characteristic fundus features observed with multimodal imaging, retinal specialists made a diagnosis of PIC. The patient was affected with high myopia. As her general COVID-19 symptoms disappeared, the patient was prescribed oral prednisolone 30 mg/day for 14 days to treat PIC. Fundus abnormality decreased and her ocular symptoms improved. No side effects were observed, including the recurrence of general COVID-19 symptoms. Conclusion We experienced an extremely rare case of PIC immediately after COVID-19 infection and showed the potential safety and effectiveness of oral prednisolone in treating PIC in the active phase after the disappearance of the general COVID-19 infection symptoms.https://doi.org/10.1186/s12886-022-02514-8COVID-19Oral prednisolonePunctate inner choroidopathy |
| spellingShingle | Manabu Miyata Sotaro Ooto Yuki Muraoka Punctate inner choroidopathy immediately after COVID-19 infection: a case report BMC Ophthalmology COVID-19 Oral prednisolone Punctate inner choroidopathy |
| title | Punctate inner choroidopathy immediately after COVID-19 infection: a case report |
| title_full | Punctate inner choroidopathy immediately after COVID-19 infection: a case report |
| title_fullStr | Punctate inner choroidopathy immediately after COVID-19 infection: a case report |
| title_full_unstemmed | Punctate inner choroidopathy immediately after COVID-19 infection: a case report |
| title_short | Punctate inner choroidopathy immediately after COVID-19 infection: a case report |
| title_sort | punctate inner choroidopathy immediately after covid 19 infection a case report |
| topic | COVID-19 Oral prednisolone Punctate inner choroidopathy |
| url | https://doi.org/10.1186/s12886-022-02514-8 |
| work_keys_str_mv | AT manabumiyata punctateinnerchoroidopathyimmediatelyaftercovid19infectionacasereport AT sotaroooto punctateinnerchoroidopathyimmediatelyaftercovid19infectionacasereport AT yukimuraoka punctateinnerchoroidopathyimmediatelyaftercovid19infectionacasereport |